Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2334

Sort by

Sort Order Select

Journal Articles

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Charles J. Milrod, Frances Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood (2021) 137 (21): 2987–2989.

https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Juan Pablo Alderuccio, MD, Sunil Iyer, MD, Isildinha M Reis, PhD, Alvaro J. Alencar, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 3992.

https://doi.org/10.1182/blood-2019-125004

Published: 2019

Journal Articles

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Ruihua Mi, Lin Chen, MD, Xudong Wei, PhD, Xiaojiao WANG, Yongping Song, MD

Blood (2019) 134 (Supplement_1): 3865.

https://doi.org/10.1182/blood-2019-128431

Published: 2019

Journal Articles

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Kathryn Lurain, MDMPH, Ramya Ramaswami, MBBS,MPH, Anaida Widell, RN, Irene Ekwede, RN, Jomy George, PharmD, Maryalice Stetler-Stevenson, MD PhD, Mark Raffeld, MD, Constance M. Yuan, MD PhD, Joseph Ziegelbauer, PhD, Frank Maldarelli, MD PhD, William D. Figg, PharmD, Cody Peer, PhD, Seth M. Steinberg, PhD, Denise Whitby, Thomas S. Uldrick, MD MS, Robert Yarchoan, MD

Blood (2019) 134 (Supplement_1): 4096.

https://doi.org/10.1182/blood-2019-122070

Published: 2019

Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 4024.

https://doi.org/10.1182/blood-2019-126358

Published: 2019

Journal Articles

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Michael Sebag, MD PhD, Julie Stakiw, MD, Thomas J. Stephens, Amie Padhiar, Tony Kim, Jane Shum, Sujith Dhanasiri, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 70.

https://doi.org/10.1182/blood-2019-123636

Published: 2019

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Slavisa Ninkovic, MBBS FRACP FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Lenny Straszkowski, BSci Hons, Giulia Quattrocchi, Wee-Joo Chng, MBBS, PhD, Louise E Purton, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD

Blood (2019) 134 (Supplement_1): 4376.

https://doi.org/10.1182/blood-2019-128190

Published: 2019

Journal Articles

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Jessica B Taube, MBBChir, Catherine SY Lecat, MBBS, Simon Cheesman, BPharm, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Christopher Parrish, MB BChir MA MRCP FRCPath PhD, Neil K Rabin, Sajitha Sachchithananthan, Jonathan Sive, MD, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat

Blood (2019) 134 (Supplement_1): 4340.

https://doi.org/10.1182/blood-2019-128266

Published: 2019

Journal Articles

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Katayoun Fomani, MD, Cindy Xu, Swathi Ratkal, MD, Vijay Nandi, PhD, Abena Appiah-Kubi, MD MPH, Banu Aygun, MD, James Louie, MD, Patricia Shi, MD

Blood (2019) 134 (Supplement_1): 2291.

https://doi.org/10.1182/blood-2019-122259

Published: 2019

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Ruth Wester, M Duin, King Hong Lam, MD PhD, Suzana Couto, Yan Ren, Maria Wang, Bronno Van Der Holt, PhD, Berna Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Anjan Thakurta, Sonja Zweegman, Annemiek Broyl, MD PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 3071.

https://doi.org/10.1182/blood-2019-128584

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Flora Yuen, BBiomedSc, Hannah Victoria Giles, FRCPath, MRCP, Malgorzata Gorniak, BSc, Hang Quach, MBBS, FRACP, FRCPA, MD, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP,FRCPA,MPhil,BA, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Krystal Bergin, Shreerang Sridesai, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, John Reynolds, PhD

Blood (2019) 134 (Supplement_1): 3090.

https://doi.org/10.1182/blood-2019-129760

Published: 2019

Journal Articles

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Francesco Mazziotta, MD, Gabriele Buda, MD PhD, Nadia Cecconi, MD, Giulia Cervetti, MD, Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Matteo Pelosini, MD PhD, Edoardo Benedetti, MD, Francesco Caracciolo, MD, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2019) 134 (Supplement_1): 3254.

https://doi.org/10.1182/blood-2019-126118

Published: 2019

Journal Articles

Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)

Sikander Ailawadhi, MD, Dorothy Romanus, RPh, PhD, Dasha Cherepanov, PhD, Yu Yin, MS, MA, Meng-Ru Cheng, MSPH, Parameswaran Hari, MBBS, MD

Blood (2019) 134 (Supplement_1): 3164.

https://doi.org/10.1182/blood-2019-124301

Published: 2019

Journal Articles

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Karthik Ramasamy, MBBS MRCP FRCPath PhD, Mark T Drayson, MB ChB, PhD FRCPath, Gulnaz Iqbal, PhD, Victoria Stalker, BSc, MA, Salma Akhtar, BSc, MSc, Janet Dunn, PhD, Stephen Schey, MBBS

Blood (2019) 134 (Supplement_1): 3135.

https://doi.org/10.1182/blood-2019-128157

Published: 2019

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

M Hasib Sidiqi, MBBS, Abdullah S. S. Al Saleh, MBBS, Iuliana Vaxman, MDBA, Angela Dispenzieri, MD, Francis K. Buadi, MB, CHB, Eli Muchtar, MD, Rahma M Warsame, MD, Martha Q. Lacy, MD, David Dingli, MD PhD, Nelson Leung, MD, Wilson I Gonsalves, MD, Prashant Kapoor, MD, Taxiarchis Kourelis, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD, Morie A Gertz, MD

Blood (2019) 134 (Supplement_1): 3171.

https://doi.org/10.1182/blood-2019-125453

Published: 2019

Journal Articles

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Flora Yuen, BBiomedSc, John Reynolds, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Patricia Walker, MBBS, BMedSci, FRACP, FRCPA, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Rosanne Dunn, PhD, Andrew Spencer, DM

Blood (2019) 134 (Supplement_1): 3144.

https://doi.org/10.1182/blood-2019-130084

Published: 2019

NARROW

Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R 2 ) in Primary Effusion Lymphoma in Patients with or without HIV

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Higher Intensity of Cell Surface Glucose-Regulated Protein 78 (csGRP78) Expression Is Seen in Patients with Early Progressive Disease/Mortality in a Cohort of Relapsed, Refractory Multiple Myeloma Patients Treated with Carfilzomib, Thalidomide and Dexamethasone

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Benefit and Safety of Isovolemic Hemodilution Prior to Red Cell Exchange in Chronically Transfused Sickle Cell Patients

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only